# Confidential

# 510(k) Summary: C.f.a.s. DAT Qualitative Plus Clinical and Control Set DAT Clinical

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

Submitter Name, Address, Contact

Roche Diagnostics 9115 Hague Rd. Indianapolis, IN 46250 317-521-3742

Contact Person: Michelle Neff

Date Prepared: April 2, 2009

# Proprietary and Established Names

Proprietary names: C.f.a.s. DAT Qualitative Plus Clinical Control Set DAT Clinical

Regulatory Information

# C.f.a.s. DAT Qualitative Plus Clinical

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>DKB</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>862.3200</td><td rowspan=1 colspan=1>Toxicology(91)</td></tr></table>

# Control Set DAT Clinical

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>DIF</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>862.3280</td><td rowspan=1 colspan=1>Toxicology(91)</td></tr></table>

# Confidential

# C.f.a.s. DAT Qualitative Plus Clinical

We claim substantial equivalence to the currently marketed Roche calibrators :

Preciset DAT Plus I Calibrators (K031775) Preciset DAT Plus II and Cfas DAT Qualitative Plus Calibrators (K033306)

# Control Set DAT Clinical

We claim substantial equivalence to the currently marketed Roche controls :

Control Set DAT I, Control Set DAT II, Control Set DAT III, (K080183)

# Confidential

C.f.a.s. DAT Qualitative Plus Clinical calibrators contain a mixture of 10 different drugs, prepared by quantitative addition of drug or drug metabolite to drug-free human urine. Drugs included are amphetamines, barbituates, benzodiazepines, cannabinoids, cocaine, methadone, methaqualone, opiates, phencyclidine, and propoxyphene. The calibrator set contains a single level for each drug in a drug mixture. Drug concentrations are verified by gas chromatography/mass spectrometry (GC/MS). Drugs or drug metabolites and their respective levels included are as follows:

Amphetamines: ${ 5 0 0 \ n g / \mathrm { m L } }$ Barbituates: $2 0 0 ~ \mathrm { n g / m L }$ EY Benzodiazepines: $\mathsf { I 0 0 \ n g / m L }$ Cannabinoids: $5 0 ~ \mathrm { n g / m L }$ EY Cocaine: $3 0 0 ~ \mathrm { n g / m L }$ EMP Methadone: ${ 3 0 0 \ n g / \mathrm { { m L } } }$ Methaqualone: $3 0 0 ~ \mathrm { n g / m L }$ Opiates: $3 0 0 ~ \mathrm { n g / m L }$ EP Phencyclidine: $2 5 \mathrm { \ n g / m L }$ Propoxyphene: $3 0 0 ~ \mathrm { n g / m L }$

Control Set DAT Clinical controls contain a mixture of 10 different drugs, prepared by quantitative addition of drug or drug metabolite to drug-free human urine. Drugs included are amphetamines, barbituates, benzodiazepines, cannabinoids, cocaine, methadone, methaqualone, opiates, phencyclidine, and propoxyphene. Drug concentrations are verified by gas chromatography/mass spectrometry (GC/MS). Target concentrations are established at $\pm 2 5 \%$ of the assay cutoff.

<table><tr><td rowspan=2 colspan=1>Drug</td><td rowspan=2 colspan=1>Assay Cutoffm(ng/mL)P</td><td rowspan=1 colspan=2>Target Concentration (ng/mL)</td></tr><tr><td rowspan=1 colspan=1>PreciNeg</td><td rowspan=1 colspan=1>XUS PreciPos</td></tr><tr><td rowspan=1 colspan=1>Amphetamines</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>625</td></tr><tr><td rowspan=1 colspan=1>Barbituates</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>250</td></tr><tr><td rowspan=1 colspan=1>Benzodiazepines</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>125</td></tr><tr><td rowspan=1 colspan=1>Cannabinoids</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>37.5</td><td rowspan=1 colspan=1>62.5</td></tr><tr><td rowspan=1 colspan=1>Cocaine</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>375</td></tr><tr><td rowspan=1 colspan=1>Methadone</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>375</td></tr><tr><td rowspan=1 colspan=1>Methaqualone</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>375</td></tr><tr><td rowspan=1 colspan=1>Opiates</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>375</td></tr><tr><td rowspan=1 colspan=1>Phencyclidine</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>18.8</td><td rowspan=1 colspan=1>31.3</td></tr><tr><td rowspan=1 colspan=1>Propoxyphene</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>375</td></tr></table>

# Confidential

# Intended Use

The C.f.a.s. DAT Qualitative Plus Clinical calibrator is designed for the qualitative calibration of the Roche assays for drugs of abuse in human urine on automated clinical chemistry analyzers.

The Control Set DAT Clinical is for use as an assayed control in the Roche test system for qualitative and semiquantitative determination of drugs of abuse in human urine on automated clinical chemistry analyzers.

mparison to the The recommended controls to be used with the proposed ONLINE edicate Device Amphetamines II assay are the Control Set DAT I, Control Set DAT . II, Control Set DAT III (K080183).

# Confidential

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=3>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>C.f.a.s. DATQualitative PlusClinical</td><td rowspan=1 colspan=1>Preciset DATPlus ICalibrators</td><td rowspan=1 colspan=1>Preciset DATPlus II</td><td rowspan=1 colspan=1>Cfas DATQualitative PlusCalibrators</td></tr><tr><td rowspan=1 colspan=1>IntendedUse</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Designed for thecalibration of theRoche assays fordrugs of abusein human urineon automatedclinicalchemistryanalyzers.</td><td rowspan=1 colspan=1>Designed for thecalibration of theRoche assays fordrugs of abuse inhuman urine onautomatedclinicalchemistryanalyzers.</td><td rowspan=1 colspan=1>Designed for thecalibration of theRoche assays fordrugs of abusein human urineon automatedclinicalchemistryanalyzers.</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=1>AmphetaminesBarbituatesBenzodiazepinesCannabinoidsCocaineMethadoneMethaqualoneOpiatesPhencyclidinePropoxyphene</td><td rowspan=1 colspan=1>AmphetaminesBarbituatesBenzodiazepinesCannabinoidsCocaineMethadoneOpiatesPhencyclidinePropoxyphene</td><td rowspan=1 colspan=1>BenzodiazepinesOpiates</td><td rowspan=1 colspan=1>BarbituatesBenzodiazepinesCocaineMethadoneOpiatesPhencyclidinePropoxyphene</td></tr><tr><td rowspan=1 colspan=1>Form</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Liquid</td><td rowspan=1 colspan=1>Liquid</td><td rowspan=1 colspan=1>Liquid</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>GC/MS</td><td rowspan=1 colspan=1>GC/MS</td><td rowspan=1 colspan=1>GC/MS</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Human urinebased</td><td rowspan=1 colspan=1>Human urinebased</td><td rowspan=1 colspan=1>Human urinebased</td></tr><tr><td rowspan=1 colspan=1>Number ofLevels</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Up to 6</td><td rowspan=1 colspan=1>Up to 6</td><td rowspan=1 colspan=1>1</td></tr></table>

Page 5 of 6   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Control Set DAT Clinical</td><td rowspan=1 colspan=1>Control Set DAT I, Control SetDAT II, Control Set DAT III</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>For use as an assayed control inthe Roche test system for thequalitative and semiquantitativedetermination of drugs of abuse inhuman urine on automated clinicalchemistry analyzers.</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Amphetamines (d-methamphetamine)Barbituates (secobarbital)Benzodiazepines (nordiazepam)Cannabinoids (A THC-COOH)Cocaine (benzoylecgonine)</td></tr></table>

# Confidential

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Methadone (dl-methadone)Methaqualone (methaqualone)Opiates (d-morphine)PCP (phencyclidine)Propoxyphene (propoxyphene)</td></tr><tr><td rowspan=1 colspan=1>Form</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Liquid</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>GC/MS</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Human urine based</td></tr><tr><td rowspan=1 colspan=1>Number ofLevels</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td></tr></table>

# JUN 18 2009

Roche Diagnostics ATTN: Ms. Michelle L. Neff 9115 Hague Road Indianapolis, IN 46250

Re: k090939 Trade/Device Name: Roche C.F.A.S. DAT Qualitative Plus Clinical calibrator and Control Set DAT Clinical Regulation Number: 21 CFR $\ S 8 6 2 . 3 2 8 0$ Regulation Name: Clinical toxicology control material. Regulatory Class: Class II Product Code: DKB, DIF Dated: April 2, 2009 Received: April 3, 2009

Dear Ms. Neff:

We have reviewed your Section $5 1 0 ( \mathbf { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure)to legally marketed predicate devices marketed ininterstate commrce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

yur evic caseeboveito ither classpal olssâ…¢ may be subject to such additional controls. Existing major regulations affecting your device can be in Ti , Cod  Federal Regulations (CFR), Parts 800 to 8. In aiion, FDAy publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page - 2

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. For more information regarding the reporting of adverse events, please go to http://www.fda.gov/cdrh/mdr/.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Intemet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/b7f3cb2b77f339a89114a37d5832b6b15ca62b151400575b87045d9319ce51ad.jpg)

Chdrtney C. Harper, Ph.D.   
Acting Director   
Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Enclosure

# Indication for Use

510(k) Number (if known): K090939

Device Name: C.f.a.s. DAT Qualitative Plus Clinical & Control Set DAT Clinical

Indication For Use:

The C.f.a.s. DAT Qualitative Plus Clinical calibrator is designed for the qualitative calibration of the Roche assays for drugs of abuse in human urine on automated clinical chemistry analyzers.

The Control Set DAT Clinical is for use as an assayed control in the Roche test system for qualitative and semiquantitative determination of drugs of abuse in human urine on automated clinical chemistry analyzers.

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/5a341ee53ee965c2ed6c0b8ab81098c49d8297c7c583104d00567d4ef09d6b18.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

Page 1 of 1